Hemostemix Inc. (CVE:HEM – Get Free Report) fell 14.5% on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. 438,482 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The firm has a 50-day moving average of C$0.12 and a 200-day moving average of C$0.09. The firm has a market capitalization of C$24.39 million, a P/E ratio of -14.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What is the Dogs of the Dow Strategy? Overview and Examples
- Oracle Announces Game-Changing News for the AI Industry
- Following Congress Stock Trades
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Dividend Capture Strategy: What You Need to Know
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
